FRAMINGHAM, Mass., May 24, 2011 /PRNewswire/ — Framingham-based
Boston Heart Lab announced that it is changing its name to Boston
Heart Diagnostics. The company launched its new name and logo at
the National Lipid Association Scientific Sessions conference, held
May 19-22 in New York City.
(Logo:
http://photos.prnewswire.com/prnh/20110524/NE03671LOGO)
“We work hard to earn our reputation every day as a
high-science, high-service company that’s approachable and
efficient — delivering value to patients and clinicians far beyond
lab results,” said President and CEO Susan Hertzberg. “That’s why
Boston Heart Lab is becoming Boston Heart
Diagnostics. We believe our new name and logo better reflect
who we are, what we do, and our patient-focused mission.”
Boston Heart Diagnostics focuses solely on cardiovascular
disease (CVD) — the number one cause of death in the United
States. Estimates are that there are 19 million people in the U.S.
with diagnosed heart disease and another 45 million at risk. CVD is
complicated, and every one of these patients is different. Named
“most promising early stage company” in 2009 by Silicon Ventures,
the company’s services fall within the sweet spot of the changing
healthcare paradigm known as personalized medicine.
The goal is to improve outcomes for patients and save health
dollars by tailoring a therapeutic regimen to the patient’s
particular circumstances. Cardiovascular disease is ripe for this
approach. Researchers are gaining valuable new insights into the
causes of CVD and the role of lipid disorders in its progression.
There are also promising new drugs in development. The company’s
growing suite of cardiac panels and other diagnostic tests are
designed to provide the specific patient insight that clinicians
need to determine which of the many available therapies is the
right one and what lifestyle changes will help produce better
health outcomes. Follow-up diagnostic services allow t
‘/>”/>
